CSLLY
Price:
$93.83
Market Cap:
$90.87B
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufact...[Read more]
Industry
Biotechnology
IPO Date
2009-12-29
Stock Exchange
PNK
Ticker
CSLLY
According to CSL Limited’s latest financial reports and current stock price. The company's current Enterprise Value is 101.39B. This represents a change of 52.46% compared to the average of 66.50B of the last 4 quarters.
The mean historical Enterprise Value of CSL Limited over the last ten years is 91.54B. The current 101.39B Enterprise Value has changed 10.98% with respect to the historical average. Over the past ten years (40 quarters), CSLLY's Enterprise Value was at its highest in in the June 2020 quarter at 138.27B. The Enterprise Value was at its lowest in in the March 2024 quarter at 0.
Average
91.54B
Median
95.32B
Minimum
42.50B
Maximum
136.05B
Discovering the peaks and valleys of CSL Limited Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 37.57%
Maximum Annual Enterprise Value = 136.05B
Minimum Annual Increase = -35.71%
Minimum Annual Enterprise Value = 42.50B
Year | Enterprise Value | Change |
---|---|---|
2024 | 104.78B | 5.15% |
2023 | 99.65B | 16.59% |
2022 | 85.47B | -35.71% |
2021 | 132.96B | -2.28% |
2020 | 136.05B | 33.00% |
2019 | 102.30B | 12.43% |
2018 | 90.98B | 37.57% |
2017 | 66.14B | 21.23% |
2016 | 54.56B | 28.35% |
2015 | 42.50B | 26.87% |
The current Enterprise Value of CSL Limited (CSLLY) is greater than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
96.63B
5-year avg
111.78B
10-year avg
91.54B
CSL Limited’s Enterprise Value is less than Novo Nordisk A/S (3.34T), greater than BeiGene, Ltd. (21.31B), greater than Acelyrin, Inc. (453.74M), greater than Caribou Biosciences, Inc. (200.91M), greater than Molecular Partners AG (57.62M), greater than Mineralys Therapeutics, Inc. (603.45M), greater than AN2 Therapeutics, Inc. (5.46M), greater than Pharvaris N.V. (844.30M), greater than PepGen Inc. (174.61M), greater than Ventyx Biosciences, Inc. (122.28M), greater than CSL Limited (97.32B), greater than Bionomics Limited (-9094838.00), greater than Enzon Pharmaceuticals, Inc. (-40291832.00), greater than Cogent Biosciences, Inc. (1.23B), greater than Larimar Therapeutics, Inc. (453.31M), greater than Kura Oncology, Inc. (1.34B), greater than Kiniksa Pharmaceuticals, Ltd. (1.46B), greater than Cerevel Therapeutics Holdings, Inc. (8.24B), greater than Revolution Medicines, Inc. (9.07B), greater than Nuvalent, Inc. (6.17B), greater than RAPT Therapeutics, Inc. (47.88M), greater than Syndax Pharmaceuticals, Inc. (1.51B), greater than EQRx, Inc. (826.94M),
Company | Enterprise Value | Market cap |
---|---|---|
3.34T | $486.89B | |
21.31B | $22.84B | |
453.74M | $580.88M | |
200.91M | $211.45M | |
57.62M | $247.30M | |
603.45M | $671.31M | |
5.46M | $32.23M | |
844.30M | $1.29B | |
174.61M | $221.28M | |
122.28M | $151.94M | |
97.32B | $86.82B | |
-9094838.00 | $8.81M | |
-40291832.00 | $5.94M | |
1.23B | $1.30B | |
453.31M | $483.02M | |
1.34B | $1.36B | |
1.46B | $1.55B | |
8.24B | $8.19B | |
9.07B | $9.33B | |
6.17B | $6.25B | |
47.88M | $79.23M | |
1.51B | $1.61B | |
826.94M | $1.14B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like CSL Limited using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like CSL Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is CSL Limited's Enterprise Value?
What is the highest Enterprise Value for CSL Limited (CSLLY)?
What is the 3-year average Enterprise Value for CSL Limited (CSLLY)?
What is the 5-year average Enterprise Value for CSL Limited (CSLLY)?
How does the current Enterprise Value for CSL Limited (CSLLY) compare to its historical average?